The prognostic role of a gene signature from tumorigenic breast-cancer cells
Copyright 2007 Massachusetts Medical Society..
BACKGROUND: Breast cancers contain a minority population of cancer cells characterized by CD44 expression but low or undetectable levels of CD24 (CD44+CD24-/low) that have higher tumorigenic capacity than other subtypes of cancer cells.
METHODS: We compared the gene-expression profile of CD44+CD24-/low tumorigenic breast-cancer cells with that of normal breast epithelium. Differentially expressed genes were used to generate a 186-gene "invasiveness" gene signature (IGS), which was evaluated for its association with overall survival and metastasis-free survival in patients with breast cancer or other types of cancer.
RESULTS: There was a significant association between the IGS and both overall and metastasis-free survival (P<0.001, for both) in patients with breast cancer, which was independent of established clinical and pathological variables. When combined with the prognostic criteria of the National Institutes of Health, the IGS was used to stratify patients with high-risk early breast cancer into prognostic categories (good or poor); among patients with a good prognosis, the 10-year rate of metastasis-free survival was 81%, and among those with a poor prognosis, it was 57%. The IGS was also associated with the prognosis in medulloblastoma (P=0.004), lung cancer (P=0.03), and prostate cancer (P=0.01). The prognostic power of the IGS was increased when combined with the wound-response (WR) signature.
CONCLUSIONS: The IGS is strongly associated with metastasis-free survival and overall survival for four different types of tumors. This genetic signature of tumorigenic breast-cancer cells was even more strongly associated with clinical outcomes when combined with the WR signature in breast cancer.
| Errataetall: |
CommentIn: N Engl J Med. 2007 Jan 18;356(3):294-7. - PMID 17229957 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2007 |
|---|---|
| Erschienen: |
2007 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:356 |
|---|---|
| Enthalten in: |
The New England journal of medicine - 356(2007), 3 vom: 18. Jan., Seite 217-26 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Rui [VerfasserIn] |
|---|
| Themen: |
CD24 Antigen |
|---|
| Anmerkungen: |
Date Completed 22.01.2007 Date Revised 08.04.2022 published: Print CommentIn: N Engl J Med. 2007 Jan 18;356(3):294-7. - PMID 17229957 Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM167756133 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM167756133 | ||
| 003 | DE-627 | ||
| 005 | 20231223113635.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2007 xx |||||o 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0559.xml |
| 035 | |a (DE-627)NLM167756133 | ||
| 035 | |a (NLM)17229949 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Rui |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The prognostic role of a gene signature from tumorigenic breast-cancer cells |
| 264 | 1 | |c 2007 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.01.2007 | ||
| 500 | |a Date Revised 08.04.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: N Engl J Med. 2007 Jan 18;356(3):294-7. - PMID 17229957 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright 2007 Massachusetts Medical Society. | ||
| 520 | |a BACKGROUND: Breast cancers contain a minority population of cancer cells characterized by CD44 expression but low or undetectable levels of CD24 (CD44+CD24-/low) that have higher tumorigenic capacity than other subtypes of cancer cells | ||
| 520 | |a METHODS: We compared the gene-expression profile of CD44+CD24-/low tumorigenic breast-cancer cells with that of normal breast epithelium. Differentially expressed genes were used to generate a 186-gene "invasiveness" gene signature (IGS), which was evaluated for its association with overall survival and metastasis-free survival in patients with breast cancer or other types of cancer | ||
| 520 | |a RESULTS: There was a significant association between the IGS and both overall and metastasis-free survival (P<0.001, for both) in patients with breast cancer, which was independent of established clinical and pathological variables. When combined with the prognostic criteria of the National Institutes of Health, the IGS was used to stratify patients with high-risk early breast cancer into prognostic categories (good or poor); among patients with a good prognosis, the 10-year rate of metastasis-free survival was 81%, and among those with a poor prognosis, it was 57%. The IGS was also associated with the prognosis in medulloblastoma (P=0.004), lung cancer (P=0.03), and prostate cancer (P=0.01). The prognostic power of the IGS was increased when combined with the wound-response (WR) signature | ||
| 520 | |a CONCLUSIONS: The IGS is strongly associated with metastasis-free survival and overall survival for four different types of tumors. This genetic signature of tumorigenic breast-cancer cells was even more strongly associated with clinical outcomes when combined with the WR signature in breast cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a CD24 Antigen |2 NLM | |
| 650 | 7 | |a Hyaluronan Receptors |2 NLM | |
| 700 | 1 | |a Wang, Xinhao |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Grace Y |e verfasserin |4 aut | |
| 700 | 1 | |a Dalerba, Piero |e verfasserin |4 aut | |
| 700 | 1 | |a Gurney, Austin |e verfasserin |4 aut | |
| 700 | 1 | |a Hoey, Timothy |e verfasserin |4 aut | |
| 700 | 1 | |a Sherlock, Gavin |e verfasserin |4 aut | |
| 700 | 1 | |a Lewicki, John |e verfasserin |4 aut | |
| 700 | 1 | |a Shedden, Kerby |e verfasserin |4 aut | |
| 700 | 1 | |a Clarke, Michael F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d 1945 |g 356(2007), 3 vom: 18. Jan., Seite 217-26 |w (DE-627)NLM000008184 |x 1533-4406 |7 nnns |
| 773 | 1 | 8 | |g volume:356 |g year:2007 |g number:3 |g day:18 |g month:01 |g pages:217-26 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 356 |j 2007 |e 3 |b 18 |c 01 |h 217-26 | ||